Glaxosmithkline | GSK - Cash And Equivalent


Glaxosmithkline reported GBP3.44B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Aurora Cannabis CAD 64.69M 8.33M Mar/2026
Bausch Health Companies USD 1.83B 526M Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Canopy Growth CAD 364.68M 6.64M Mar/2026
Corcept Therapeutics USD 111.04M 2.3M Jun/2026
Drreddys Laboratories INR 15.37B 3.29B Mar/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Glaxosmithkline GBP 3.44B 146M Mar/2026
J&J USD 20.42B 1.27B Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Novartis USD 7.62B 739M Jun/2026
Pacira USD 205.88M 61.57M Jun/2026
Perrigo USD 357.2M 174.4M Mar/2026
Pfizer USD 976M 727M Jun/2026
Phibro Animal Health USD 61.42M 6.49M Jun/2026
Prestige Brands USD 89.13M 25.26M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
Supernus Pharmaceuticals USD 179.95M 4.92M Jun/2026
Takeda JPY 460.98B 134.07B Jun/2026
Teva Pharmaceutical Industries USD 3.74B 185M Mar/2026
Zoetis USD 1.48B 465M Jun/2026